

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Twelve month prevalence of haemarthrosis and joint disease using the haemophilia joint health score; evaluation of the UK National Haemophilia Database and Haemtrack patient reported data

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-052358
Article Type:	Original research
Date Submitted by the Author:	14-Apr-2021
Complete List of Authors:	<p>Wilkins, Richard; University of Leeds Leeds Institute of Rheumatic and Musculoskeletal Medicine; Leeds Teaching Hospitals NHS Trust, Leeds haemophilia Comprehensive Care Centre</p> <p>Stephensen, David; East Kent Hospitals University NHS Foundation Trust, Haemophilia Centre; Barts Health NHS Trust, Haemophilia Centre</p> <p>Siddle, Heidi; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine</p> <p>Scott, Martin; Manchester Royal Infirmary, University Department of Clinical Haematology,; The University of Manchester, Institute of Cancer Sciences, Faculty of Biology, Medicine and Health</p> <p>Xiang, Hua; UKHCDO National Haemophilia Database</p> <p>Horn, Elizabeth; Leeds Teaching Hospitals NHS Trust, Leeds haemophilia Comprehensive Care Centre</p> <p>Palmer, Ben; UKHCDO National Haemophilia Database</p> <p>Chapman, Graham; University of Central Lancashire, School of Sport and Health Sciences</p> <p>Richards, Michael ; Leeds Teaching Hospitals NHS Trust, Leeds haemophilia Comprehensive Care Centre</p> <p>Walwyn, Rebecca; University of Leeds, Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research</p> <p>Redmond, Anthony; University of Leeds, Leeds Institute of Rheumatology and Musculoskeletal Medicine; Leeds Teaching Hospitals NHS Trust, NIHR Leeds Biomedical Research Centre</p>
Keywords:	Bleeding disorders & coagulopathies < HAEMATOLOGY, Foot & ankle < ORTHOPAEDIC & TRAUMA SURGERY, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Twelve-month prevalence of haemarthrosis and joint disease using the**
5 **haemophilia joint health score; evaluation of the UK National Haemophilia**
6 **Database and Haemtrack patient reported data.**
7
8
9

10 Richard A Wilkins^{1,2}, David Stephensen^{3,4} Heidi J Siddle¹, Martin J. Scott^{5,6}, Hua Xiang⁷,
11 Elizabeth Horn², Ben Palmer⁷, Graham J Chapman⁸, Michael Richards², Rebecca Walwyn⁹,
12 Anthony C Redmond^{1,10}.
13
14
15
16

- 17 1. Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of
18 Leeds, Leeds, UK
- 19 2. Leeds haemophilia Comprehensive Care Centre, Leeds Teaching Hospitals NHS
20 trust, Leeds, UK
- 21 3. The Royal London Hospital Haemophilia Centre, Barts and The London School of
22 Medicine and Dentistry, Queen Mary University London, London, UK
- 23 4. Kent Haemophilia & Thrombosis Centre, East Kent Hospitals University NHS Trust,
24 Canterbury, UK
- 25 5. University Department of Clinical Haematology, Manchester Royal Infirmary,
26 Manchester, UK
- 27 6. Institute of Cancer Sciences, Faculty of Biology, Medicine and Health, The
28 University of Manchester, Manchester, UK
- 29 7. UKHCDO National Haemophilia Database, Manchester, UK
- 30 8. School of Sport and Health Sciences, University of Central Lancashire, Preston, UK
- 31 9. Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University
32 of Leeds, Leeds, UK
- 33 10. NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust,
34 Leeds, UK
- 35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Correspondence:**
4

5 Richard A Wilkins, Section of Clinical Biomechanics and Physical Medicine, Leeds Institute of
6 Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
7
8

9
10 Email: r.a.wilkins@leeds.ac.uk
11

12
13 **Key words:** Prevalence, haemarthrosis, haemarthropathy, annualised joint bleed rate,
14 haemophilia joint health score, prophylaxis
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract (300 words) for BMJ open

Objectives: To report the 12 month prevalence of joint bleeding and joint disease status at an individual joint level, in children and adults with severe haemophilia A and B without a current inhibitor.

Methods and analysis: Application was made to the UK National Haemophilia Database (NHD) with a request for the following; Haemtrack patient reported treatment record and Haemophilia Joint Health Scores (HJHS) in children (<18y) and adults (≥18y) with severe haemophilia A (HA) and B (HB) (FVIII/FIX, <0.01 iu/ml) without a current inhibitor. Data were collated and reported for 1st January to 31st December 2018.

Results: 2238 cases were identified, 463 patients had fully itemised HJHS of whom 273 were Haemtrack compliant. The median (IQR) age of children was 10 (6-13) and adults 40 (29-50) years. Haemarthrosis prevalence in HA/HB children was 33% and 47%, respectively and 60% and 42%, respectively, in adults. The most common site of haemarthrosis in children was the knee in HA and ankle in HB. In adults, the incidence of haemarthrosis at the ankles and elbows was equal. Median (IQR) total HJHS in HA/HB children were 0 (0;0). In adults with HA/HB, HJHS were 18 (6; 31) and 11 (5; 24), respectively. In adults with HA/HB, mean (SD) ankle HJHS of 3.8 (4.1) and median 4.0 (0.0; 8.0) were higher than the knee (mean 2.9 (4.1) and median 1.0 (0.0; 5.0) and elbow (mean 3.3 (4.1) and median 1.0 (0.0; 7.0) joints.

Conclusion; During 2018, NHD prevalence data for haemarthrosis indicate that only two-thirds of children and one-third of adults from a UK cohort compliant with prophylaxis were bleed free. Median HJHS of zero in children suggests joint disease status is either unaffected during childhood or undetected by the HJHS. In adults, moderately higher HJHS are reported for the ankles indicating worse joint health.

Strength and limitations of the study (methodology)

- This study reports the 12 month prevalence of haemarthrosis in children and adults with severe haemophilia without current inhibitors, and associated HJHS as a measure of joint disease
- Prevalence and site were collated retrospectively from Haemtrack and HJHS from the National Haemophilia Database
- Only the most compliant of patients who were adherent to taking and reporting prophylaxis on a national electronic treatment diary Haemtrack with concurrent HJHS scores were included
- Sample size was affected by methodology in including those with electronic fully itemised HJHS and above 75% threshold of compliance.
- The design of this study does not allow us to observe longitudinal joint bleed or joint health status.

Introduction:

Haemophilia is a rare x-linked recessive genetic disorder characterised by bleeding into soft tissue and joints [1]. The most common forms are haemophilia A and B, affecting 1:10000 and between 1:35,000 and 1:50,000 respectively. The disease is further characterised by the levels of factor VIII (FVIII) and factor IX (FIX), with the most severely affected having less than 1% (<0.01 IU/mL) circulating clotting factor (severe haemophilia) [2]. Musculoskeletal bleeding is the most common haemorrhagic manifestation, with 90% of bleeds occurring in muscles or joints [1]. The presence of blood products within the joint space and the process of removal leads to synovial hypertrophy, haemosiderin deposition and eventually arthropathic joint changes [3]. Over time, repeated haemarthrosis results in chronic synovitis, changes in cartilage and bone composition and progressive chronic haemarthropathy [4, 5].

Infusion of replacement clotting factor concentrates (CFC) is prescribed with the aim of elevating circulating factor to a level that halts spontaneous and traumatic bleeding [1]. CFC treatment is not without complication. The development of anti-Factor antibodies or “inhibitors” in some people produces an immune response to CFC infusion that significantly reduces the effectiveness of CFC treatment. Development of inhibitors increase the risk of bleeding, joint damage and requirement for factor treatment bypassing agents [6]. Ultimately the aim of modern treatment of haemophilia is prevention of joint bleeds with a target of achieving zero bleeds whenever possible. Prevention of haemarthrosis in all age groups is important and in particular in children, where musculoskeletal immaturity exposes joints to greater risk of damage in later life. Multiple studies have shown that early initiation of CFC prophylaxis in children delays joint damage and reduces joint disease [7-10]. In adults, multi-joint haemarthropathy remains a common feature of the disease, but even prophylaxis started in adulthood decreases bleeding, improves pain and improves health related QoL (HRQoL) [11]. Therefore in children and adults prophylaxis is considered the standard of care for all patients [11, 12]. Traditionally, prophylactic treatment in severe haemophilia aims to maintain factor VIII (FVIII) or Factor IX (FIX) at a trough level >0.01 iu/ml. It is apparent that many patients

1
2
3 experience spontaneous as well as traumatic bleeds, despite achieving trough factor levels >
4 0.01 iu/ml. Several approaches have been adopted or are being investigated with the aim of
5 attaining complete bleed avoidance, including more individualised treatment with standard
6 half-life products, the use of coagulation factors with extended half-lives, and innovative non-
7 factor treatments [12-15].
8
9

10
11
12
13
14 Recent evaluation of real world treatment regimes in severe and moderate haemophilia in the
15 UK and Europe, has shown that despite adequate coagulation factor concentrate availability,
16 treatment is still suboptimal. In 2015, data from the United Kingdom National Haemophilia
17 Database (NHD) reported median (IQR) annualised bleed rates (ABR)/ annualised joint bleed
18 rates (AJBR) in children (0-11y) and adolescents (12-18y) of 1.0 (0.0-0.5)/ 0.0 (0.0-1.0) and
19 2.0 (0.0-7.0)/ 1.0 (0.0-3.0), respectively. ABR in adults with severe haemophilia A on
20 prophylaxis were 2.0 (IQR 0.0-7.0) and AJBR was 1.0 (IQR 0.0-4.0) with only 29% bleed free
21 and 34% joint bleed free [16]. Similarly, reported European (Belgium, France, Germany, Italy,
22 Spain, Sweden, and UK) data shows median AJBR of 1.0 – 4.0. [16, 17]. However, data on
23 bleeding frequency and severity of haemarthropathy at an individual joint level is lacking.
24
25
26
27
28
29
30
31
32
33
34

35
36 The main sites of haemarthrosis are the elbows, ankles and the knees, with the shoulders,
37 wrists and hips less commonly affected and data for these sites not collated by the NHD or
38 recorded as part of the HJHS [18]. Incidence of haemarthrosis and joint disease at an
39 individual joint level are unknown. Those deemed most compliant with prophylaxis are less
40 likely to experience repeated incidents of haemarthrosis and therefore less likely to have
41 established joint disease when compared to those who do not adhere to treatment. This may
42 be a smaller proportion than those who do not adhere to treatment but these cases are
43 important in gauging the efficacy of current treatments [11, 19, 20]. Understanding prevalence
44 and joint disease in the most compliant of patients may provide direction for future research
45 of patient compliance and management of joint disease, including non-pharmacological
46 interventions and intra-articular therapies commonly used in the management of MSK
47 conditions.
48
49
50
51
52
53
54
55
56
57
58
59
60

Objective

The primary objective of this study is to determine the prevalence and incidence of joint bleeding and joint disease using the HJHS at an individual joint level in children and adults with severe haemophilia A and B without a current inhibitor.

For peer review only

Methods:

Ethical approval was obtained on 24th January 2017 (IRAS: 206141, R&D: PD16/227) Approval to access data from the UKHCDO NHD Data Analysis Group was granted on 12th July 2019 and the analysis report produced by UKHCDO on the 4th October 2019. The study has been reported in accordance with the UKHCDO NHD guidelines and regulations.

Data on bleed prevalence and site were collated retrospectively from Haemtrack and Haemophilia Joint Health Scores from the National Haemophilia Database. Haemtrack is a UK national online treatment diary in which individual patients regularly report details of treatments with coagulation factor concentrates (CFC) [20, 21]. Details of home delivery of CFC treatment to patients is recorded by the corresponding haemophilia treatment centre and then uploaded to the NHD. When CFC is administered by the patient that individual treatment is then recorded on Haemtrack, including the reason for each treatment such as prophylaxis or bleed treatment and the site of each bleed. Data recorded in Haemtrack are then integrated with NHD [20]. The 2018-2019 UKHCDO report indicated median compliance at haemophilia comprehensive care centres (CCC) and haemophilia treatment centres (HC) of 90% and 93% respectively [22]. The HJHS is a measure of joint health status in patients with haemophilia and forms part of the UKHCDO haemophilia management guidelines [23, 24]. The HJHS Version 2.1 is collated as six individual joint scores (0-20) and compiled with a global gait score (0-4) to a total score (0-124). A higher HJHS score represents worse joint health.

Participants were children (<18 years old) and adults (≥18 years old) with severe haemophilia A and B (FVIII or FIX <0.01 IU/mL) without a current inhibitor, who had been issued with coagulation factor concentrates in the UK between 1st January and 31st December 2018. Regular prophylaxis was defined for those using standard half-life (SHL) prophylaxis as ≥2 infusions per week for Haemophilia A, and ≥1 infusions/week for haemophilia B for >45 weeks/year; for patients using extended half-life (EHL) products, ≥1 infusions/week for haemophilia A, and more than once every two weeks for haemophilia B for >45 weeks/year. Low dose prophylaxis is not prescribed in the UK, therefore, prophylaxis was assumed as

1
2
3 above 25 IU/kg to maintain a trough level above 0.02 IU/ml [25]. Those included in the analysis
4 were Haemtrack compliant (defined as recorded use of $\geq 75\%$ of received factor concentrate)
5 with a corresponding electronically recorded Haemophilia Joint Health Score (HJHS) Version
6
7
8
9
10 2.1.

11
12 The joint bleed prevalence (%) for paediatric and adult patients and AJBR and HJHS were
13 collated from Haemtrack and NHD. AJBR were reported by patients through the Haemtrack
14 and recorded over the 12-month study period (1st January to 31st December 2018). Adequate
15 primary and secondary prophylaxis and adherence to treatment are known to reduce bleed
16 rates and reduce the burden of joint disease [11, 19]. Therefore only data from the most
17 compliant patients ($\geq 75\%$ received factor concentrate vs recorded in Haemtrack) were
18 reported as per the NHD standard operating procedure for data analysis and reporting. Joint
19 bleed prevalence, AJBR and HJHS are reported for all joints (total) and in each individual joint.
20 Data are summarised using means and standard deviations (SD) or medians and interquartile
21 ranges (IQR, 25; 75 percentiles).
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Patient and Public Involvement:** Patients from the Leeds Haemophilia Comprehensive Care
39 Centre, Leeds, UK and The NIHR Leeds Biomedical Research Centre (BRC), Leeds, UK were
40 involved in the original design of the author's clinical doctoral research fellowship and this
41 original article.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results:

During 2018, 2238 individuals with severe haemophilia A (n=1889) and B (n=349) without a current inhibitor were registered with the NHD and 1396 were registered with Haemtrack. Electronically recorded fully itemised HJHS data was available for 463 patients with contemporaneous Haemtrack available for 273 individuals of whom 86.8% (n=237) had haemophilia A and 13.2% (n=36) haemophilia B. Participant age and treatment characteristics are presented in Table 1.

Table 1: Participant characteristics

Patient characteristics	Haemophilia A		Haemophilia B	
	Age < 18 (n=80)	Age ≥ 18 (n=157)	Age < 18 (n=17)	Age ≥ 18 (n=19)
Age (median, IQR)	10 (7; 13)	40 (29; 50)	12 (7;14)	45 (25; 48)
SHL	67% (n=54)	77% (n=121)	18% (n=3)	32%(n=6)
EHL	29% (n=23)	23% (n=36)	70% (n=12)	42%(n=8)
SHL-EHL	4% (n=3)	0%	12% (n=2)	26% (n=5)

SHL= Standard Half-life product, EHL= Extended Half-life product, SHL-EHL=switch from a SHL to a EHL during the 12 month study period.

Joint bleed prevalence and annualised bleed rate

Joint bleed prevalence and individual joint bleed incidence are categorised by age, haemophilia type and joint, and are presented in Table 2. Children with haemophilia A (32.5%) and haemophilia B (47.1%) reported at least one incidence of joint bleeding. Adults with haemophilia A (59.9%) and B (42.1%) reported at least one bleed over the same time period. Mean AJBR by ankles, knees, and elbows are presented in Figure 1.

Figure 1: Combined AJBR for children and adults with severe haemophilia A and B.

Table 2. Annual joint bleed prevalence and AJBR of children and adults

Annual Joint Bleeds			Haemophilia A		Haemophilia B	
Joint			Age < 18 (n=80)	Age ≥ 18 (n=157)	Age < 18 (n=17)	Age ≥ 18 (n=19)
All Joints	Joint bleed prevalence	n (%)	26 (32.5)	94 (59.9)	8 (47.1)	8 (42.1)
	Annual joint bleed Rate	Mean (SD)	0.81 (1.68)	3.90 (7.00)	1.00 (1.18)	2.04 (3.59)
		Median (IQR)	0.0 (0.0;1.0)	1.0 (0.0;4.4)	0.0 (0.0;2.0)	0.0 (0.0;3.5)
Right Ankle	Joint bleed prevalence	n (%)	2 (2.5)	27 (17.2)	1 (5.9)	2 (10.5)
	Annual joint bleed Rate	Mean (SD)	0.08 (0.57)	0.38 (1.06)	0.06 (0.24)	0.16 (0.51)
		Median (IQR)	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.0 (0.0;0.0)
Left ankle	Joint bleed prevalence	n (%)	5 (6.3)	35 (22.3)	5 (29.4)	2 (10.5)
	Annual joint bleed Rate	Mean (SD)	0.10 (0.44)	0.61 (1.98)	0.36 (0.62)	0.11 (0.33)
		Median (IQR)	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.0 (0.0;1.0)	0.0 (0.0;0.0)
Right knee	Joint bleed prevalence	n (%)	13 (16.3)	27 (17.2)	1 (5.9)	2 (10.5)
	Annual joint bleed Rate	Mean (SD)	0.20 (0.56)	0.41 (1.48)	0.18 (0.73)	0.53 (2.08)
		Median (IQR)	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.0 (0.0;0.0)
Left knee	Joint bleed prevalence	n (%)	7 (8.8)	24 (15.3)	1 (5.9)	2 (10.5)
	Annual joint bleed Rate	Mean (SD)	0.11 (0.39)	0.29 (0.96)	0.10 (0.42)	0.21 (0.72)
		Median (IQR)	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.0 (0.0;0.0)
Right elbow	Joint bleed prevalence	n (%)	6 (8.0)	29 (18.5)	1 (5.9)	3 (15.8)
	Annual joint bleed Rate	Mean (SD)	0.08 (0.27)	0.39 (1.12)	0.06 (0.24)	0.28 (0.78)
		Median (IQR)	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.0 (0.0;0.0)
Left elbow	Joint bleed prevalence	n (%)	4 (5.0)	35 (22.3)	1 (5.9)	2 (10.5)
	Annual joint bleed Rate	Mean (SD)	0.12 (0.73)	0.81 (2.38)	0.06 (0.24)	0.17 (0.53)
		Median (IQR)	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.0 (0.0;0.0)	0.0 (0.0;0.0)

Joint bleed prevalence (%): Numerator = number of patients who had bleeds, Denominator = total cohort number,

Haemophilia joint health score

HJHS categorised by age, haemophilia type and joint are presented in Table 3. Median (IQR) of HJHS in children were 0.0 (0.0; 0.0) in both haemophilia A and B. In adults the total HJHS were higher than in children; the total HJHS is higher in haemophilia A than haemophilia B. At an individual joint level both mean (SD) and median (IQR) ankle HJHS of 4.6 (4.3)/ 4.0 (0.0; 8.0) were higher than for the knee 2.9 (4.1)/ 1.00 (0.0; 5.0) and elbow 3.3 (4.1)/ 1.0 (0.0; 7.0).

Table 3. Haemophilia joint health scores for children and adults

Haemophilia joint health scores			Haemophilia A		Haemophilia B	
Joint			Age < 18 (n=80)	Age ≥ 18 (n=157)	Age < 18 (n=17)	Age ≥ 18 (n=19)
All Joints	HJHS (total)	Mean (SD)	0.7 (1.0)	21.2 (16.8)	0.4 (0.9)	15.4 (15.1)
		Median (IQR)	0.0 (0.0;0.0)	18.0 (6.0;31.0)	0.0 (0.0;0.0)	11.0 (5.0;24.0)
Right Ankle	HJHS (total)	Mean (SD)	0.1 (0.4)	4.6 (4.2)	0.0 (0.0)	3.6 (4.1)
		Median (IQR)	0.0 (0.0;0.0)	4.0 (0.0;8.0)	0.0 (0.0;0.0)	2.0 (0.0;7.0)
Left ankle	HJHS (total)	Mean (SD)	0.0 (0.1)	4.6 (4.3)	0.3 (0.8)	4.8 (4.1)
		Median (IQR)	0.0 (0.0;0.0)	4.0 (0.0;8.0)	0.0 (0.0;0.0)	4.0 (1.0;8.0)
Right knee	HJHS (total)	Mean (SD)	0.2 (0.5)	2.7 (3.9)	0.0 (0.0)	2.5 (4.6)
		Median (IQR)	0.0 (0.0;0.0)	1.0 (0.0;4.0)	0.0 (0.0;0.0)	0.0 (0.0;1.0)
Left knee	HJHS (total)	Mean (SD)	0.1 (0.3)	2.9 (4.1)	0.1 (0.2)	1.3 (2.2)
		Median (IQR)	0.0 (0.0;0.0)	1.00 (0.0;5.0)	0.0 (0.0;0.0)	0.0 (0.0;2.0)
Right elbow	HJHS (total)	Mean (SD)	0.1 (0.7)	3.3 (4.1)	0.0 (0.0)	1.3 (2.6)
		Median (IQR)	0.0 (0.0;0.0)	1.0 (0.0;7.0)	0.0 (0.0;0.0)	0.0 (0.0;1.0)
Left elbow	HJHS (total)	Mean (SD)	0.2 (1.2)	3.2 (4.2)	0.1 (0.2)	2.1 (4.0)
		Median (IQR)	0.0 (0.0;0.0)	1.0 (0.0;6.0)	0.0 (0.0;0.0)	0.0 (0.0;1.0)

HJHS: Global Gait score not included

Discussion:

In this study we report the current prevalence of haemarthrosis in children and adults with severe haemophilia without current inhibitors, and associated HJHS as a measure of joint disease. The study was conducted retrospectively, using data from 2018 in a national database. In a national cohort of 2338 individuals, 463 patients had electronically-recorded fully itemised HJHS, with the sample size further reduced to 273 patients who met the fully Haemtrack compliant criteria. During the data collection period, 62% of the national cohort used HT, 20% of whom fulfilled compliance criteria set by the NHD, permitting analysis of haemarthrosis and joint health status of a representative sample of UK with severe haemophilia without inhibitors. The sample size whilst small is focused only the most compliant of patients and provides insight to the current compliance rates and reporting of joint diseases to the NHD. The results presented in this paper represent the likely best case scenario for the most complaint cases and this further highlight the 80% of patients who fail to either record or comply with treatment and raises questions as to the real compliance and adherence to treatment, as well as the concurrent joint disease in patients who do not meet the 75% NHD inclusion threshold.

In children with severe haemophilia, average AJBR were low across haemophilia types. One in three children did however experience a joint bleed during the 12-month data collection period. The majority of those included would have typically been provided prophylaxis from an early age and continue to adhere to a prophylaxis regime, but 30% of children still experienced haemarthrosis during the 12 month data collection period. HJHS itemised by joint were very low in children (Table 3) suggesting either minimal joint disease or that the HJHS might not be sensitive to early joint changes following haemarthrosis. Reliability of the HJHS has been explored in children and young adults and is reported to be sensitive to early joint changes [23, 26] , although individual joint HJHS of less than three at the knee and ankle are less able to identify pathological joint change when compared to MRI and US imaging [27]. Canine, mouse and human in-vitro models have demonstrated chondrocyte apoptosis and reduced

1
2
3 proteoglycan synthesis affecting cartilage matrix turnover within 48-96 hours of an induced
4 joint bleed, suggesting a single joint bleed may have detrimental effects on joint cartilage [28-
5 30]. Formally reported bleed rates in the NHD are relatively low, however micro bleeding
6 (subclinical bleeding not clinically detectable, or experienced by the patient) is an emerging
7 theme in haemophilia. Episodes of subclinical bleeding may contribute to the deterioration of
8 joint health despite no clinically detectable signs of a joint bleed [3].
9
10
11
12
13
14

15
16 In the adult population, AJBR were higher than those reported in children, with mean (SD)
17 AJBR of 3.9 (7.0) and median (IQR) 1.0 (0.0-4.4) in haemophilia A and 2.0 (3.6) and 0.0 (0.0-
18 3.5) in haemophilia B, respectively. The 12-month prevalence was also higher, with 60% and
19 41% of adults with haemophilia A and B, respectively, experiencing at least one bleed over
20 the period. HJHS scores at the ankle joint were similar to the elbows, with knees slightly less
21 affected. Interestingly the median scores at both the knee and elbow were lower than that of
22 the ankle, suggesting that there is worse ankle joint health overall when compared to other
23 joints. Ankle joint changes are driven by the mechanical demand on the ankle and forces
24 exerted on the joint during activities of daily living, in combination with structural and functional
25 changes often seen in adolescents and adults with severe haemophilia [31, 32]. Our data
26 suggest that very early signs of joint disease might not be detected by the HJHS; rather it
27 measures the cumulative effect of haemarthropathy, not detectable until later years.
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 AJBR in this study are slightly lower (Table 2) than those reported in the UK THUNDER study
43 conducted three years earlier using the same NHD database [11]. Scott et al. reported a
44 median AJBR of 0.0 in children (0-11 years), 1.0 in adolescents (12-18 years) and 3.0 in adults
45 aged 19 and above. Our prevalence data (Table 1) for both children and adults indicate a
46 slight decrease AJBR since the Scott et al. study [16]. In terms of the treatment profile of those
47 included in our study, about one quarter were now using an EHL product and 96% of those
48 sampled are receiving and are compliant with treatment. In addition Scott et al did not include
49 those patients with haemophilia B who are reported to have better joint health and less
50 frequent joint bleeds [33]. Regardless, those sampled in this study still had up to four joint
51
52
53
54
55
56
57
58
59
60

1
2
3 bleeds over a 12-month period, with 60% of all adults reporting a minimum of one joint bleed.
4
5 Forty percent of individuals sampled reported no bleeds and were well controlled, but for the
6
7 remaining 60% it is unclear why joint bleeding occurred. Understanding why the 60% in this
8
9 cohort reported haemarthrosis may lead to better targeted and individualised treatment and
10
11 identification of other contributing factors such as lifestyle and altered, combined and individual
12
13 joint biomechanics of the upper and lower limbs.
14
15

16 A limitation of this study is the low proportion of patients registered on the UK database that
17
18 had full Haemtrack and itemised HJHS data recorded at the time of data collection. The NHD
19
20 does not report bleed level data on patients who do not use Haemtrack owing to the difficulty
21
22 in collecting data from paper diaries and established links at each haemophilia centre through
23
24 the NHD Haemophilia Centre Information System (HCIS), limiting analysis to Haemtrack
25
26 compliant users [20]. Bias may have been introduced by the study design through the inability
27
28 to include those not recording treatment in Haemtrack and those for whom HJHS examinations
29
30 were not reported or itemised by joint to the NHD. Although this is the largest reported dataset
31
32 of HJHS, the lack of linkage between elements of the data limits its wider utility. As electronic
33
34 reporting of HJHS to the NHD becomes more routine and the dataset expands, we will be able
35
36 link HJHS and joint health to rates of haemarthrosis. Haemtrack data compliance is defined
37
38 as $\geq 75\%$ of home delivery treatment received being recorded as used by the patient and so
39
40 those who met the inclusion criteria are regarded as “good reporters” and deemed likely to be
41
42 compliant with treatment [20]. The current bleeding and joint disease profiles of those who
43
44 receive and record treatment, but fall below the 75% treatment adherence criteria is unknown.
45
46 Access to individual treatment dose and trough levels were not available from the database
47
48 and is acknowledged as a limitation of this study. Reporting of these data relies on haemophilia
49
50 centres uploading real time data, including trough levels and up to date measurements of
51
52 weight but requires access to patient’s data and requires better reporting methods to be
53
54 achievable. Understanding joint haemarthrosis in this subset of patients may provide further
55
56 insight into the real-world prevalence of haemarthrosis. As expected due to the lower
57
58
59
60

1
2
3 prevalence, the sample of haemophilia B patients in this analysis is smaller than the
4 haemophilia A cohort, and therefore differences in joint bleed prevalence and HJHS between
5 patients with haemophilia A and B should be interpreted with caution. Those with haemophilia
6 B may present with a milder bleeding phenotype than that of haemophilia A regardless of
7 severity or treatment [33-35]. In addition people with haemophilia B may display less severe
8 levels of haemarthropathy, with differences in the specific pathophysiological mechanisms of
9 joint disease underlined by different rates of joint deterioration and severity [36]. Direct
10 comparison between disease types is limited and therefore further research is needed to
11 explore whether the lower bleed rates and better joint health in people with haemophilia B
12 suggested in this study can be confirmed.

13
14
15
16
17
18
19
20
21
22
23
24
25 History of spontaneous and traumatic bleeding could not be separated, owing to data reporting
26 methods within Haemtrack. Whilst prophylaxis protects against spontaneous bleeding there is
27 still a proportion of these treatment compliant adults reporting up to four joint bleeds in the 12
28 month study period. Haemarthrosis may occur as individual joint events, but our data
29 highlights the burden on overall joint disease. A previous history of developing inhibitors and
30 a history of on-demand treatment now using secondary prophylaxis may predispose patients
31 to higher levels of joint disease and greater risk of subsequent haemarthrosis [11]. Further
32 research is required therefore to understand the bleeding profile and burden of disease in
33 adults with established joint disease and previous inhibitor status.

34
35
36
37
38
39
40
41
42
43
44 A further limitation is between-centre variability in HJHS assessment [37]. HJHS data from
45 different haemophilia centres may be subject to inter-centre scoring variability, although
46 workshops have been conducted in the UK to decrease inter-centre variability in HJHS
47 scoring. Furthermore, we are unable to confirm the influence of other factors such as the
48 presence of co-morbid musculoskeletal conditions on HJHS data. UKHCDO NHD data was
49 also requested from those with moderate disease but there was insufficient data to include in
50 the analysis. Future comparison by disease severity (severe and moderate) may provide
51 further insight of those most at risk of haemarthropathy.

Clinical implication and conclusion:

In a UK cohort of Haemtrack compliant patients with severe haemophilia and without a current inhibitor, only 70% of children and 30% of adults remained haemarthrosis free during 2018. Haemarthrosis was most likely to be reported in the knee joint in children with haemophilia A, the ankle joint in children with haemophilia B, the elbow and ankle joint in adults with haemophilia A, and the elbow joint in adults with haemophilia B. Overall higher HJHS were reported for the ankle joint compared to the knee and elbow, suggesting that the ankle joint is the most severely compromised joint in people with haemophilia.

Investigation of impact on function and potential interventions that lessen the burden of disease are warranted. Future clinical studies would also benefit from understanding the bleeding profiles of those who do not meet compliance criteria for Haemtrack or other database-linked bleed data to obtain the true prevalence of haemarthrosis and joint disease.

Abbreviations

ABR: Annual bleed rate

AJBR: Annual joint bleed rate

CFC: Clotting factor concentrate

EHL: Extended half life

HJHS: Haemophilia joint health score

NHD: National Haemophilia Database

SHL: Standard half-life

UKHCDO: United Kingdom Haemophilia Doctors Organisation

Declarations

Ethics approval and consent to participate

Ethical approval was obtained to allow access the National Haemophilia Database, anonymised data. This study was approved by London Queen Square Research Ethics Committee (16/LO/2251) and NHS Health research Authority (IRAS ID 206141). Individual participant consent was not applicable.

Consent for publication

Consent to publish this paper was obtained from the UKHCDO NHD.

Availability of data and materials

The data that support the findings of this study are available from The National Haemophilia Database (NHD) but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the corresponding author upon reasonable request and with permission of the NHD.

Competing interests

RAW has received registration fees and support for travel from Roche.

DS has received research funding from Sobi, CSL and Roche; consultancy and speakers fees from Sobi and Takeda

EH has received speaker fees from Roche, sponsorship for travel from Sobi.

MJS has received research funding from Bayer; consultancy and speakers fees from Sobi and Roche; registration fees and support for travel from Sobi, Pfizer and CSL.

HJS is a HEE/NIHR Senior Clinical lecturer and has received funding from NIHR who also funded this research.

ACR is a NIHR Senior Investigator and has received funding from NIHR who also funded this research.

GJC, RW, HX, BP and MR report no competing interests

Funding

1
2
3 RAW is funded by a National Institute for Health Research (NIHR) Clinical Doctoral Research
4 Fellowship (ICA-CDRF-2015-01-0120); ACR is in part supported through the NIHR Leeds
5 Biomedical Research Centre, Leeds, UK. This paper presents independent research funded
6 by the National Institute for Health Research (NIHR). The views expressed are those of the
7 authors and not necessarily those of the NHS, the NIHR or the Department of Health.
8
9
10
11
12

13 **Author's contributions**

14 The study was conceived by RAW, AR, GC, RW and HJS. Analysis was undertaken by
15 members of staff at the NHD (HX and BP). The manuscript was written by RAW and DS.
16 Subsequent drafts were edited and approved by RAW, DS, MJS, AR, GC, MR, EH, HJS, and
17 RW.
18
19
20
21
22
23
24
25
26

27 **Acknowledgements**

28 The authors would like to thank the centre directors, physiotherapists and staff of all UK
29 haemophilia centres for their hard work in collecting data and responding to data queries. We
30 would also like to thank the members of the UKHCDO Data Analysis Group for advising on
31 data interpretation; Prof Charles Hay, Prof Peter Collins, Dr Elizabeth Chalmers, Dr Ryan
32 Cheal, Prof Pratima Chowdary, Simon Fletcher, Dr Georgina Hall, Dr Dan Hart, Dr Ri Liesner,
33 Andrew McNally, Ben Palmer, Paul Sartain, Dr Martin Scott, Dr Susie Shapiro, David
34 Stephensen, Dr Hua Xiang. The staff at the National Haemophilia Database are also thanked
35 for their contribution to data collection.
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Author's information**

51 **ORCID (those with ORCID IDs)**

52 Richard Wilkins: 0000-0003-1885-5472

53 Anthony Redmond: 0000-0002-8709-9992

54 Heidi Siddle: 0000-0002-6015-332X
55
56
57
58
59
60

1
2
3 Graham Chapman: 0000-0003-3983-6641
4

5
6 Martin Scott: 0000-0002-0854-1309
7

8 David Stephensen: 0000-0002-6175-3343
9

10
11 Rebecca Walwyn: 0000-0001-9120-1438
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

1. Bolton-Maggs, P.H. and K.J. Pasi, *Haemophilias a and b*. The Lancet, 2003. **361**(9371): p. 1801-1809.
2. Biggs, R. and R.J.B.j.o.h. Macfarlane, *Haemophilia and related conditions: a survey of 187 cases*. 1958. **4**(1): p. 1-27.
3. Gringeri, A., B. Ewenstein, and A.J.H. Reiningger, *The burden of bleeding in haemophilia: is one bleed too many?* Haemophilia, 2014. **20**(4): p. 459-463.
4. Van Vulpen, L., K. Holstein, and C.J.H. Martinoli, *Joint disease in haemophilia: Pathophysiology, pain and imaging*. Haemophilia, 2018. **24**: p. 44-49.
5. Roosendaal, G. and F. Lafeber, *Pathogenesis of haemophilic arthropathy*. Haemophilia, 2006. **12**(s3): p. 117-121.
6. Hanley, J., et al., *Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia*. Haemophilia, 2017.
7. Manco-Johnson, M.J., et al., *Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia*. New England Journal of Medicine, 2007. **357**(6): p. 535-544.
8. Oldenburg, J., *Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens*. Blood, 2015. **125**(13): p. 2038-44.
9. Gringeri, A., et al., *A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)*. Journal of Thrombosis and Haemostasis, 2011. **9**(4): p. 700-710.
10. Srivastava, A., et al., *Guidelines for the management of hemophilia*. 2013. **19**(1): p. e1-e47.
11. Collins, P., et al., *Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study*. Journal of Thrombosis and Haemostasis, 2010. **8**(1): p. 83-89.
12. Skinner, M.W., et al., *Achieving the unimaginable: Health equity in haemophilia*. Haemophilia, 2019.
13. Skinner, M.W., *WFH: closing the global gap—achieving optimal care*. Haemophilia, 2012. **18**: p. 1-12.
14. Ebbert, P.T., et al., *Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors*. Haemophilia, 2020. **26**(1): p. 41-46.
15. Chowdary, P.J.T.R., *Extended half-life recombinant products in haemophilia clinical practice—Expectations, opportunities and challenges*. Thrombosis Research, 2019.
16. Scott, M.J., et al., *Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study*. Haemophilia, 2019. **25**(2): p. 205-212.
17. Berntorp, E., et al., *European retrospective study of real-life haemophilia treatment*. Haemophilia, 2017. **23**(1): p. 105-114.
18. Stephensen, D., et al., *Changing patterns of bleeding in patients with severe haemophilia A*. Haemophilia, 2009. **15**(6): p. 1210-1214.
19. Thornburg, C.D., N.A.J.P.p. Duncan, and adherence, *Treatment adherence in hemophilia*. Patient preference adherence, 2017. **11**: p. 1677.
20. Hay, C., et al., *The haemtrack home therapy reporting system: Design, implementation, strengths and weaknesses: A report from UK Haemophilia Centre Doctors Organisation*. Haemophilia, 2017. **23**(5): p. 728-735.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
21. UKHCDO. *united kingdom haemophilia centre doctors organisation*. 2020 [cited 2020 05/04/2020]; Available from: <http://www.ukhcdo.org/nhd/>.
22. UKHCDO, *UKHCDO Annual Report 2019, including bleeding disorder statistics 2019*.
23. Hilliard, P., et al., *Hemophilia joint health score reliability study*. *Haemophilia*, 2006. **12**(5): p. 518-525.
24. Ribeiro, T., et al., *Developing a new scoring scheme for the Hemophilia Joint Health Score 2.1*. *Research and practice in thrombosis and haemostasis*, 2019. **3**(3): p. 405-411.
25. Richards, M., et al., *A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A*. 2010. **149**(4): p. 498-507.
26. Boehlen, F., L. Graf, and E.J.E.J.o.H. Berntorp, *Outcome measures in haemophilia: a systematic review*. 2014. **93**: p. 2-15.
27. Poonnoose, P., et al., *Correlating clinical and radiological assessment of joints in haemophilia: results of a cross sectional study*. *Haemophilia*, 2016. **22**(6): p. 925-933.
28. Hakobyan, N., et al., *Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene*. *Blood*, 2004. **104**(7): p. 2060-2064.
29. Roosendaal, G., et al., *Blood-induced joint damage: a canine in vivo study*. *Haemophilia*, 1999. **42**(5): p. 1033-1039.
30. Hooiveld, M., et al., *Blood-induced joint damage: longterm effects in vitro and in vivo*. *The Journal of rheumatology*, 2003. **30**(2): p. 339-344.
31. Pasta, G., et al., *Orthopaedic management of haemophilia arthropathy of the ankle*. *Haemophilia*, 2008. **14**(s3): p. 170-176.
32. Rodriguez-Merchan, E.C., *Management of hemophilic arthropathy of the ankle*. *Cardiovascular and Hematological Disorders - Drug Targets*, 2017. **17**(2): p. 111-118.
33. Mannucci, P. and M.J.H. Franchini, *Is haemophilia B less severe than haemophilia A?* *Haemophilia*, 2013. **19**(4): p. 499-502.
34. Santagostino, E., et al., *Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile*. *Journal of Thrombosis and Haemostasis* 2010. **8**(4): p. 737-743.
35. Castaman, G. and D.J.h. Matino, *Hemophilia A and B: molecular and clinical characteristics of similar, but different diseases*. *Haematologica* 2019: p. haematol. 2019.221093.
36. Melchiorre, D., et al., *Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A*. *Haematologica*, 2016. **101**(2): p. 219-225.
37. Nijdam, A., et al., *Using routine Haemophilia Joint Health Score for international comparisons of haemophilia outcome: standardization is needed*. *Haemophilia* 2016. **22**(1): p. 142-147.




Figure 1: Combined AJBR for children and adults with severe haemophilia A and B.

BMJ Open

Twelve-month prevalence of haemarthrosis and joint disease using the haemophilia joint health score; evaluation of the UK National Haemophilia Database and Haemtrack patient reported data: an observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-052358.R1
Article Type:	Original research
Date Submitted by the Author:	02-Sep-2021
Complete List of Authors:	<p>Wilkins, Richard; University of Leeds Leeds Institute of Rheumatic and Musculoskeletal Medicine; Leeds Teaching Hospitals NHS Trust, Leeds haemophilia Comprehensive Care Centre</p> <p>Stephensen, David; East Kent Hospitals University NHS Foundation Trust, Haemophilia Centre; Barts Health NHS Trust, Haemophilia Centre</p> <p>Siddle, Heidi; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine</p> <p>Scott, Martin; Manchester Royal Infirmary, University Department of Clinical Haematology,; The University of Manchester, Institute of Cancer Sciences, Faculty of Biology, Medicine and Health</p> <p>Xiang, Hua; UKHCDO National Haemophilia Database</p> <p>Horn, Elizabeth; Leeds Teaching Hospitals NHS Trust, Leeds haemophilia Comprehensive Care Centre</p> <p>Palmer, Ben; UKHCDO National Haemophilia Database</p> <p>Chapman, Graham; University of Central Lancashire, School of Sport and Health Sciences</p> <p>Richards, Michael ; Leeds Teaching Hospitals NHS Trust, Leeds haemophilia Comprehensive Care Centre</p> <p>Walwyn, Rebecca; University of Leeds, Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research</p> <p>Redmond, Anthony; University of Leeds, Leeds Institute of Rheumatology and Musculoskeletal Medicine; Leeds Teaching Hospitals NHS Trust, NIHR Leeds Biomedical Research Centre</p>
Primary Subject Heading:	Haematology (incl blood transfusion)
Secondary Subject Heading:	Rehabilitation medicine
Keywords:	Bleeding disorders & coagulopathies < HAEMATOLOGY, Foot & ankle < ORTHOPAEDIC & TRAUMA SURGERY, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open: first published as 10.1136/bmjopen-2021-052358 on 12 January 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **1 Twelve-month prevalence of haemarthrosis and joint disease using the**
5 **2 haemophilia joint health score; evaluation of the UK National Haemophilia**
6 **3 Database and Haemtrack patient reported data: an observational study**
7
8
9 **4**

10 Richard A Wilkins^{1,2}, David Stephensen^{3,4} Heidi J Siddle¹, Martin J. Scott^{5,6}, Hua Xiang⁷,
11 Elizabeth Horn², Ben Palmer⁷, Graham J Chapman⁸, Michael Richards², Rebecca Walwyn⁹,
12 Anthony C Redmond^{1,10}.
13
14
15
16 **8**

- 17
18 **9** 1. Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of
19 Leeds, Leeds, UK
20
21 **10** 2. Leeds haemophilia Comprehensive Care Centre, Leeds Teaching Hospitals NHS
22 trust, Leeds, UK
23
24 **11** 3. The Royal London Hospital Haemophilia Centre, Barts and The London School of
25 Medicine and Dentistry, Queen Mary University London, London, UK
26
27 **12** 4. Kent Haemophilia & Thrombosis Centre, East Kent Hospitals University NHS Trust,
28 Canterbury, UK
29
30 **13** 5. University Department of Clinical Haematology, Manchester Royal Infirmary,
31 Manchester, UK
32
33 **14** 6. Institute of Cancer Sciences, Faculty of Biology, Medicine and Health, The
34 University of Manchester, Manchester, UK
35
36 **15** 7. UKHCDO National Haemophilia Database, Manchester, UK
37
38 **16** 8. School of Sport and Health Sciences, University of Central Lancashire, Preston, UK
39
40 **17** 9. Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University
41 of Leeds, Leeds, UK
42
43 **18** 10. NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust,
44 Leeds, UK
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 Correspondence:**
4

5
6 **2** Richard A Wilkins, Section of Clinical Biomechanics and Physical Medicine, Leeds Institute of
7
8 **3** Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
9

10
11 **4** Email: r.a.wilkins@leeds.ac.uk
12

13 **5 Key words:** Prevalence, haemarthrosis, haemarthropathy, annualised joint bleed rate,
14
15 **6** haemophilia joint health score, prophylaxis
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **1 Abstract (300 words) for BMJ open**
4

5
6 **2 Objectives:** To report the 12 month prevalence of joint bleeds from the national haemophilia
7
8 **3** database (NHD) and Haemtrack, a patient-reported online treatment diary; and concurrent
9
10 **4** joint disease status using the haemophilia joint health score (HJHS) at individual joint level, in
11
12 **5** children and adults with severe haemophilia A and B without a current inhibitor.
13

14
15 **6 Design:** A 2018 retrospective database study of NHD from which 2238 cases were identified,
16
17 **7** 463 patients had fully itemised haemophilia joint health scores (HJHS) of whom 273 were
18
19 **8** compliant in recording treatment using Haemtrack.
20

21
22 **9 Setting:** England, Wales and Scotland, UK.
23

24
25 **10 Participants:** Children (<18y) and adults (≥18y) with severe haemophilia A (HA) and B (HB)
26
27 **11** (FVIII/FIX, <0.01 iu/ml) without a current inhibitor.
28

29
30 **12 Primary and secondary outcomes:** Prevalence of joint haemarthrosis, and concurrent joint
31
32 **13** health measured using the Haemophilia Joint Health Scores (HJHS).
33

34
35 **14 Results:** The median (IQR) age of children was 10 (6-13) and adults 40 (29-50) years.
36
37 **15** Haemarthrosis prevalence in HA/HB children was 33% and 47%, respectively and 60% and
38
39 **16** 42%, respectively, in adults. The most common site of haemarthrosis in children was the knee
40
41 **17** in HA and ankle in HB. In adults, the incidence of haemarthrosis at the ankles and elbows was
42
43 **18** equal. The median total HJHS in HA/HB children was 0 and in adults with HA/HB, were 18
44
45 **19** and 11 respectively. In adults with HA/HB, the median ankle HJHS of 4.0 was higher than the
46
47 **20** median HJHS of 1.0 for both the knee and elbow.
48

49
50 **21 Conclusion;** Despite therapeutic advances, only two-thirds of children and one-third of adults
51
52 **22** were bleed-free, even in a UK cohort selected for high compliance with prophylaxis. The
53
54 **23** median HJHS of zero in children suggests joint health is relatively unaffected during childhood.
55
56 **24** In adults, bleed rates were highest in ankles and elbows, but the ankles led to substantially
57
58 **25** worse joint health scores.
59
60

1 **Strength and limitations of the study (methodology)**

- 2 • This study reports the 12 month prevalence of haemarthrosis in children and adults
3 with severe haemophilia without current inhibitors, and associated HJHS as a measure
4 of joint disease
- 5 • Prevalence and site were collated retrospectively from Haemtrack and HJHS from the
6 National Haemophilia Database
- 7 • Only the most compliant of patients who were adherent to taking and reporting
8 prophylaxis on a national electronic treatment diary Haemtrack with concurrent HJHS
9 scores were included
- 10 • Sample size was affected by methodology including those with electronic fully itemised
11 HJHS and above 75% threshold of compliance.
- 12 • The design of this study does not allow examination of longitudinal joint bleed or joint
13 health status.

1 Introduction:

2 Haemophilia is a rare x-linked recessive genetic disorder characterised by bleeding into soft
3 tissue and joints [1]. The most common forms are haemophilia A and B, affecting 1:10000 and
4 between 1:35,000 and 1:50,000 respectively. The disease is further characterised by the
5 levels of factor VIII (FVIII) and factor VIX (FVIX), with the most severely affected having less
6 than 1% (<0.01 IU/mL) circulating clotting factor (severe haemophilia) [2]. Musculoskeletal
7 bleeding is the most common haemorrhagic manifestation, with 90% of bleeds occurring in
8 muscles or joints [1]. The presence of blood products within the joint space and the process
9 of removal leads to synovial hypertrophy, haemosiderin deposition and eventually arthropathic
10 joint changes [3]. Over time, repeated haemarthrosis results in chronic synovitis, changes in
11 cartilage and bone composition and progressive chronic haemarthropathy [4, 5].

12 Infusion of replacement clotting factor concentrates (CFC) is prescribed with the aim of
13 elevating circulating factor to a level that halts spontaneous and traumatic bleeding [1]. CFC
14 treatment is not without complication. The development of anti-Factor antibodies or “inhibitors”
15 in some people produces an immune response to CFC infusion that significantly reduces the
16 effectiveness of CFC treatment. Development of inhibitors increase the risk of bleeding, joint
17 damage and requirement for factor treatment bypassing agents [6]. Ultimately the aim of
18 modern treatment of haemophilia is prevention of joint bleeds with a target of achieving zero
19 bleeds whenever possible. Prevention of haemarthrosis in all age groups is important and in
20 particular in children, where musculoskeletal immaturity exposes joints to greater risk of
21 damage in later life. Multiple studies have shown that early initiation of CFC prophylaxis in
22 children delays joint damage and reduces joint disease [7-10]. In adults, multi-joint
23 haemarthropathy remains a common feature of the disease, but even prophylaxis started in
24 adulthood decreases bleeding, improves pain and improves health related quality of life
25 (HRQoL) [11]. Therefore in children and adults prophylaxis is considered the standard of care
26 for all patients [11, 12]. Traditionally, prophylactic treatment in severe haemophilia aims to
27 maintain Factor VIII (FVIII) or Factor IX (FIX) at a trough level >0.01 iu/ml. It is apparent that

1 many patients experience spontaneous as well as traumatic bleeds, despite achieving trough
2 Factor levels > 0.01 iu/ml. Several approaches have been adopted or are being investigated
3 with the aim of attaining complete bleed avoidance, including more individualised treatment
4 with standard half-life products, the use of coagulation factors with extended half-lives, and
5 innovative non-Factor treatments [12-15].

6 Recent evaluation of real world treatment regimes in severe and moderate haemophilia in the
7 UK and Europe, has shown that despite adequate coagulation factor concentrate availability,
8 treatment is still suboptimal. In 2015, data from the United Kingdom National Haemophilia
9 Database (NHD) reported median (IQR) annualised bleed rates (ABR)/ annualised joint bleed
10 rates (AJBR) in children (0-11y) and adolescents (12-18y) of 1.0 (0.0-0.5)/ 0.0 (0.0-1.0) and
11 2.0 (0.0-7.0)/ 1.0 (0.0-3.0), respectively. ABR in adults with severe haemophilia A on
12 prophylaxis were 2.0 (IQR 0.0-7.0) and AJBR was 1.0 (IQR 0.0-4.0) with only 29% bleed free
13 and 34% joint bleed free [16]. Similarly, reported European (Belgium, France, Germany, Italy,
14 Spain, Sweden, and UK) data shows median AJBR of 1.0 – 4.0. [16, 17]. However, data on
15 bleeding frequency and severity of haemarthropathy at an individual joint level is lacking.

16 The main sites of haemarthrosis are the elbows, ankles and the knees, with the shoulders,
17 wrists and hips less commonly affected and data for these sites not collated by the NHD. The
18 haemophilia joint health score (HJHS) is a standardised clinical assessment tool developed to
19 assess upper and lower limb joint health status. The clinical assessments undertaken by
20 specialist physiotherapists at 6-12 month intervals include measurement of swelling,
21 alignment, range of motion, and muscle atrophy, and forms part of the UKHCDO haemophilia
22 management guidelines [18, 19]. The HJHS is the most widely used score of joint health in
23 haemophilia and has shown good to moderate correlations with radiological scores of joint
24 disease using the Pettersson score [18]. However haemarthrosis is not reported by the HJHS
25 and therefore incidence of haemarthrosis and joint disease at an individual joint level are
26 unknown [20].

1
2
3 1 Those deemed most compliant with prophylaxis are less likely to experience repeated
4
5 2 incidents of haemarthrosis and therefore less likely to have established joint disease when
6
7 3 compared to those who do not adhere to treatment. This may be a smaller proportion than
8
9 4 those who do not adhere to treatment but these cases are important in gauging the efficacy
10
11 5 of current treatments [11, 19, 20]. Understanding prevalence and joint disease in the most
12
13 6 compliant of patients may provide direction for future research of patient compliance and
14
15 7 management of joint disease, including non-pharmacological interventions and intra-articular
16
17 8 therapies commonly used in the management of MSK conditions.
18
19
20
21 9
22

23 10 **Objective**

24
25
26 11 The primary objective of this study is to determine the prevalence and incidence of joint
27
28 12 bleeding and joint disease using the HJHS at an individual joint level in children and adults
29
30 13 with severe haemophilia A and B without a current inhibitor.
31
32
33 14
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **1 Methods:**

5 2 Ethical approval was obtained on 24th January 2017 (IRAS: 206141, R&D: PD16/227)
6
7 3 Approval to access data from the UKHCDO NHD Data Analysis Group was granted on 12th
8
9 4 July 2019 and the analysis report produced by UKHCDO on the 4th October 2019. The study
10
11 5 has been reported in accordance with the UKHCDO NHD guidelines and regulations.

12
13
14 6 Data on bleed prevalence and site were collated retrospectively from the Haemtrack patient
15
16 7 therapy recording system and the clinical Haemophilia Joint Health Score from the National
17
18 8 Haemophilia Database. Haemtrack is a UK national online treatment diary in which individual
19
20 9 patients regularly report details of treatments with coagulation factor concentrates (CFC) [20,
21
22 10 21]. Details of home delivery of CFC treatment to patients is recorded by the corresponding
23
24 11 haemophilia treatment centre and then uploaded to the NHD. When CFC is administered by
25
26 12 the patient that individual treatment is then recorded on Haemtrack, including the reason for
27
28 13 each treatment such as prophylaxis or bleed treatment and the site of each bleed. Data
29
30 14 recorded in Haemtrack are then integrated with NHD [20]. The 2018-2019 UKHCDO report
31
32 15 indicated median compliance at haemophilia comprehensive care centres (CCC) and
33
34 16 haemophilia treatment centres (HC) of 90% and 93% respectively with the NHD definition of
35
36 17 compliance recorded use of $\geq 75\%$ of received factor concentrate [22]. The HJHS Version 2.1
37
38 18 is collated as six individual joint scores (0-20) and compiled with a global gait score (0-4) to a
39
40 19 total score (0-124). A higher HJHS score represents worse joint health.

41
42
43
44 20 Participants were children (<18 years old) and adults (≥ 18 years old) with severe haemophilia
45
46 21 A and B (FVIII or FIX <0.01 IU/mL) without a current inhibitor, who had been issued with
47
48 22 coagulation factor concentrates in the UK between 1st January and 31st December 2018.
49
50 23 Regular prophylaxis was defined for those using standard half-life (SHL) prophylaxis as ≥ 2
51
52 24 infusions per week for Haemophilia A, and ≥ 1 infusions/week for haemophilia B for >45
53
54 25 weeks/year; for patients using extended half-life (EHL) products, ≥ 1 infusions/week for
55
56 26 haemophilia A, and more than once every two weeks for haemophilia B for >45 weeks/year.
57
58 27 Low dose prophylaxis is not prescribed in the UK, therefore, prophylaxis was assumed as
59
60

1
2
3 1 above 25 IU/kg to maintain a trough level above 0.02 IU/ml [23]. Those included in the analysis
4
5 2 were Haemtrack compliant (defined as recorded use of $\geq 75\%$ of received factor concentrate)
6
7 3 with a corresponding electronically recorded Haemophilia Joint Health Score (HJHS) Version
8
9 4 2.1.

10
11
12 5 The joint bleed prevalence (%) for paediatric and adult patients and AJBR and HJHS were
13
14 6 collated from Haemtrack and NHD. AJBR were reported by patients through the Haemtrack
15
16 7 and recorded over the 12 month study period (1st January to 31st December 2018). Adequate
17
18 8 primary and secondary prophylaxis and adherence to treatment are known to reduce bleed
19
20 9 rates and reduce the burden of joint disease [11, 19]. Therefore only data from the most
21
22 10 compliant patients ($\geq 75\%$ received factor concentrate vs recorded in Haemtrack) were
23
24 11 reported as per the NHD standard operating procedure for data analysis and reporting. Joint
25
26 12 bleed prevalence, AJBR and HJHS are reported for all joints (total) and in each individual joint.
27
28 13 Data are summarised using means and standard deviations (SD) or medians and interquartile
29
30 14 ranges (IQR, 25; 75 percentiles).
31
32
33
34
35
36
37

38 16 **Patient and Public Involvement:** Patients from the Leeds Haemophilia Comprehensive Care
39
40 17 Centre, Leeds, UK and The NIHR Leeds Biomedical Research Centre (BRC), Leeds, UK were
41
42 18 involved in the original design of the author's clinical doctoral research fellowship and this
43
44 19 original article.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Results:

2 During 2018, 2238 individuals with severe haemophilia A (n=1889) and B (n=349) without a
3 current inhibitor were registered with the NHD and 1396 were registered with Haemtrack.
4 Electronically recorded fully itemised HJHS data was available for 463 patients with
5 contemporaneous Haemtrack available for 273 individuals of whom 86.8% (n=237) had
6 haemophilia A and 13.2% (n=36) haemophilia B. Participant age and treatment characteristics
7 are presented in Table 1.

8 **Table 1: Participant characteristics**

Patient characteristics	Haemophilia A		Haemophilia B	
	Age < 18 (n=80)	Age ≥ 18 (n=157)	Age < 18 (n=17)	Age ≥ 18 (n=19)
Age (median, IQR)	10 (7; 13)	40 (29; 50)	12 (7;14)	45 (25; 48)
SHL	67% (n=54)	77% (n=121)	18% (n=3)	32% (n=6)
EHL	29% (n=23)	23% (n=36)	70% (n=12)	42% (n=8)
SHL-EHL	4% (n=3)	0%	12% (n=2)	26% (n=5)

9 SHL= Standard Half-life product, EHL= Extended Half-life product, SHL-EHL=switch from a SHL to a EHL during the 12 month study period.

11 Joint bleed prevalence and annual bleed rate

12 Joint bleed prevalence (%) and individual joint prevalence, and total AJBR are presented in
13 Table 2. Bleed data are categorised by age, haemophilia type (A and B) and the most
14 commonly affected joints (left and right) of the elbows, knees and ankles. Joint bleed prevalence
15 in children with haemophilia A (32.5%) and haemophilia B (47.1%) reported at least one
16 incidence of joint bleeding over the 12 month study period. Adults with haemophilia A (59.9%)
17 and B (42.1%) reported at least one bleed over the same time period. Median AJBR at
18 individual joints for children and adults were 0.0 (0.0;0.0) with the exception of the left ankle
19 in children with haemophilia B (0.0;1.0). Mean AJBR for adults and children at the ankles,
20 knees, and elbows are presented in Figure 1.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Figure 1: Combined annual joint bleed rate for children (vertical and horizontal black**
2 **columns) and adults (solid grey and black columns) with severe haemophilia A and B.**
3

For peer review only

1 **Table 2. Annual joint bleed prevalence and AJBR of children and adults**

Annual Joint Bleed Prevalence			Haemophilia A		Haemophilia B	
			Age < 18 (n=80)	Age ≥ 18 (n=157)	Age < 18 (n=17)	Age ≥ 18 (n=19)
Annual Joint Bleed Rate	All joints	Median (IQR)	0.0 (0.0;1.0)	1.0 (0.0;4.4)	0.0 (0.0;2.0)	0.0 (0.0;3.5)
Joint Bleed Prevalence	All joints	n (%)	26 (32.5)	94 (59.9)	8 (47.1)	8 (42.1)
	Right Ankle	n (%)	2 (2.5)	27 (17.2)	1 (5.9)	2 (10.5)
	Left ankle	n (%)	5 (6.3)	35 (22.3)	5 (29.4)	2 (10.5)
	Right knee	n (%)	13 (16.3)	27 (17.2)	1 (5.9)	2 (10.5)
	Left knee	n (%)	7 (8.8)	24 (15.3)	1 (5.9)	2 (10.5)
	Right elbow	n (%)	6 (8.0)	29 (18.5)	1 (5.9)	3 (15.8)
	Left elbow	n (%)	4 (5.0)	35 (22.3)	1 (5.9)	2 (10.5)

2 Joint bleed prevalence (%): Numerator = number of patients who had bleeds, Denominator = total cohort number,
3

1 Haemophilia joint health score

2 HJHS categorised by age, haemophilia type and joint are presented in Table 3. Median (IQR)
 3 of HJHS in children were 0.0 (0.0; 0.0) in both haemophilia A and B. In adults the total HJHS
 4 were higher than in children; the total HJHS is higher in haemophilia A than haemophilia B. At
 5 an individual joint level median (IQR) ankle HJHS of 4.0 (0.0; 8.0) were higher than for the
 6 knee 2.9 (4.1)/ 1.00 (0.0; 5.0) and elbow 3.3 (4.1)/ 1.0 (0.0; 7.0).

7 **Table 3. Haemophilia joint health scores for children and adults**

Haemophilia joint health scores	Haemophilia A		Haemophilia B	
Median (IQR)	Age < 18 (n=80)	Age ≥ 18 (n=157)	Age < 18 (n=17)	Age ≥ 18 (n=19)
All Joints	0.0 (0.0;0.0)	18.0 (6.0;31.0)	0.0 (0.0;0.0)	11.0 (5.0;24.0)
Right ankle	0.0 (0.0;0.0)	4.0 (0.0;8.0)	0.0 (0.0;0.0)	2.0 (0.0;7.0)
Left ankle	0.0 (0.0;0.0)	4.0 (0.0;8.0)	0.0 (0.0;0.0)	4.0 (1.0;8.0)
Right knee	0.0 (0.0;0.0)	1.0 (0.0;4.0)	0.0 (0.0;0.0)	0.0 (0.0;1.0)
Left knee	0.0 (0.0;0.0)	1.00 (0.0;5.0)	0.0 (0.0;0.0)	0.0 (0.0;2.0)
Right elbow	0.0 (0.0;0.0)	1.0 (0.0;7.0)	0.0 (0.0;0.0)	0.0 (0.0;1.0)
Left elbow	0.0 (0.0;0.0)	1.0 (0.0;6.0)	0.0 (0.0;0.0)	0.0 (0.0;1.0)

8 HJHS: Global Gait score not included

1 Discussion:

2 In this study we report the current prevalence of haemarthrosis in children and adults with
3 severe haemophilia without current inhibitors, and associated HJHS as a measure of joint
4 disease. The study was conducted retrospectively, using data from 2018 in a national
5 database. In a national cohort of 2338 individuals, 463 patients had electronically-recorded
6 fully itemised HJHS, with the sample size further reduced to 273 patients who met the fully
7 Haemtrack compliant criteria. During the data collection period, 62% of the national cohort
8 used Haemtrack, 20% of whom fulfilled compliance criteria set by the NHD, permitting analysis
9 of haemarthrosis and joint health status of a representative sample of UK with severe
10 haemophilia without inhibitors. The sample size whilst small is focused only the most compliant
11 of patients and provides insight to the current compliance rates and reporting of joint diseases
12 to the NHD. The results presented in this paper represent the likely best case scenario for the
13 most complaint cases and this further highlight the 80% of patients who fail to either record or
14 comply with treatment and raises questions as to the real compliance and adherence to
15 treatment, as well as the concurrent joint disease in patients who do not meet the 75% NHD
16 inclusion threshold.

17 In children with severe haemophilia, average AJBR were low across haemophilia types. One
18 in three children did however experience a joint bleed during the 12 month data collection
19 period. The majority of those included would have typically been provided prophylaxis from an
20 early age and continue to adhere to a prophylaxis regime, but 30% of children still experienced
21 haemarthrosis during the 12 month data collection period. HJHS itemised by joint were very
22 low in children (Table 3) suggesting either minimal joint disease or that the HJHS might not
23 be sensitive to early joint changes following haemarthrosis. Reliability of the HJHS has been
24 explored in children and young adults and is reported to be sensitive to early joint changes
25 [24, 25] , although individual joint HJHS of less than three at the knee and ankle are less able
26 to identify pathological joint change when compared to MRI and US imaging [18]. Similarly in
27 children, correlations between the HJHS and the Haemophilia Early Arthropathy Detection

1 with UltraSound (HEAD-US) have shown good correlations in the identification of joint
2 pathology at the elbows and knees, however at the ankles significant difference are reported
3 between HJHS and HEAD-US scores with underreporting of ankle joint pathology in both
4 instances [26]. Therefore a combined approach to joint health assessment may identify
5 pathology especially at the ankle joint prior to the progression to haemarthropathy. Canine,
6 mouse and human in-vitro models have demonstrated chondrocyte apoptosis and reduced
7 proteoglycan synthesis affecting cartilage matrix turnover within 48-96 hours of an induced
8 joint bleed, suggesting a single joint bleed may have detrimental effects on joint cartilage [27-
9 29]. Formally reported bleed rates in the NHD are relatively low, however micro bleeding
10 (subclinical bleeding not clinically detectable, or experienced by the patient) is an emerging
11 theme in haemophilia. Episodes of subclinical bleeding may contribute to the deterioration of
12 joint health despite no clinically detectable signs of a joint bleed, therefore point of care
13 ultrasound tools such as the HEAD-US may provide early evidence of joint disease [3].

14 In the adult population, AJBR were higher than those reported in children, with mean (SD)
15 AJBR of 3.9 (7.0) and median (IQR) 1.0 (0.0-4.4) in haemophilia A and 2.0 (3.6) and 0.0 (0.0-
16 3.5) in haemophilia B, respectively. The 12 month prevalence was also higher, with 60% and
17 41% of adults with haemophilia A and B, respectively, experiencing at least one bleed over
18 the period. HJHS scores at the ankle joint were similar to the elbows, with knees slightly less
19 affected. Interestingly the median scores at both the knee and elbow were lower than that of
20 the ankle, suggesting that there is worse ankle joint health overall when compared to other
21 joints. Ankle joint changes are driven by the mechanical demand on the ankle and forces
22 exerted on the joint during activities of daily living, in combination with structural and functional
23 changes often seen in adolescents and adults with severe haemophilia [30, 31]. Our data
24 suggest that very early signs of joint disease might not be detected by the HJHS; rather it
25 measures the cumulative effect of haemarthropathy, not detectable until later years.

26 AJBR in this study are slightly lower (Table 2) than those reported in the UK THUNDER study
27 conducted three years earlier using the same NHD database [11]. Scott et al. reported a

1
2
3 1 median AJBR of 0.0 in children (0-11 years), 1.0 in adolescents (12-18 years) and 3.0 in adults
4
5 2 aged 19 and above. Our prevalence data (Table 1) for both children and adults indicate a
6
7 3 slight decrease AJBR since the Scott et al. study [16]. In terms of the treatment profile of those
8
9 4 included in our study, about one quarter were now using an EHL product and 96% of those
10
11 5 sampled are receiving and are compliant with treatment. In addition Scott et al did not include
12
13 6 those patients with haemophilia B who are reported to have better joint health and less
14
15 7 frequent joint bleeds [32]. A longitudinal evaluation of tailored frequency-escalated
16
17 8 prophylaxis in a Canadian cohort of children aged 1.0 - 2.5 years (n=36) followed up over 10.2
18
19 9 years (IQR 8.5-13.6) reported median index annual haemarthrosis rates of 0.95 (0.44–1.35)
20
21 10 which is similar to our own results. Prophylaxis treatment in Canada was driven by bleed
22
23 11 incidence and escalated accordingly, so their treatment was more targeted and reactive [33].
24
25 12 The Canadian study shows that avoidance of all joint bleeding is unlikely to be possible, and
26
27 13 in our own cohort the mean (SD) AJBR of 0.81 (1.68) and 1.00 (1.18) in haemophilia A and B
28
29 14 children respectively, indicate that bleeding is occurring in some children even when compliant
30
31 15 with prophylaxis. In a Dutch study of haemophiliac adults (n=62) over a 5-10 year period with
32
33 16 a low median AJBR (IQR) 0.0 (0.0-2.0) there was still a worsening of joint health, with a HJHS
34
35 17 increase of more than 4 points over the study period in 37.1% of patients, and with the ankle
36
37 18 joints most often affected (30.6%) [34]. Those adults sampled in this study still had up to four
38
39 19 joint bleeds over a 12 month period, with 60% of all adults reporting a minimum of one joint
40
41 20 bleed. Forty percent of individuals sampled reported no bleeds and were well controlled, but
42
43 21 for the remaining 60% it is unclear why joint bleeding occurred. Understanding why the 60%
44
45 22 in this cohort reported haemarthrosis may lead to better targeted and individualised treatment
46
47 23 and identification of other contributing factors such as lifestyle and altered, combined and
48
49 24 individual joint biomechanics of the upper and lower limbs.

50
51
52
53
54 25 A limitation of this study is the low proportion of patients registered on the UK database that
55
56 26 had full Haemtrack and itemised HJHS data recorded at the time of data collection. The NHD
57
58 27 does not report bleed level data on patients who do not use Haemtrack owing to the difficulty
59
60

1
2
3 1 in collecting data from paper diaries and established links at each haemophilia centre through
4
5 2 the NHD Haemophilia Centre Information System (HCIS), limiting analysis to Haemtrack
6
7 3 compliant users [20]. Bias may have been introduced by the study design through the inability
8
9 4 to include those not recording treatment in Haemtrack and those for whom HJHS examinations
10
11 5 were not reported or itemised by joint to the NHD. Although this is the largest reported dataset
12
13 6 of HJHS, the lack of linkage between elements of the data limits its wider utility. As electronic
14
15 7 reporting of HJHS to the NHD becomes more routine and the dataset expands, we will be able
16
17 8 link HJHS and joint health to rates of haemarthrosis. Haemtrack data compliance is defined
18
19 9 as $\geq 75\%$ of home delivery treatment received being recorded as used by the patient and so
20
21 10 those who met the inclusion criteria are regarded as “good reporters” and deemed likely to be
22
23 11 compliant with treatment [20]. The current bleeding and joint disease profiles of those who
24
25 12 receive and record treatment, but fall below the 75% treatment adherence criteria is unknown.
26
27 13 Access to individual treatment dose and trough levels were not available from the database
28
29 14 and is acknowledged as a limitation of this study. Reporting of these data relies on haemophilia
30
31 15 centres uploading real time data, including trough levels and up to date measurements of
32
33 16 weight but requires access to patient’s data and requires better reporting methods to be
34
35 17 achievable. Understanding joint haemarthrosis in this subset of patients may provide further
36
37 18 insight into the real-world prevalence of haemarthrosis. This study focusses, for databasing
38
39 19 reasons, on the most compliant cases and therefore those within the broader haemophilia
40
41 20 population likely to be suffering the fewest consequences. It might be reasonable to expect
42
43 21 that over the 12 month study period, comparable patients who do not report or full comply with
44
45 22 treatment may have had higher bleed rates. Consequently it would also be expected that joint
46
47 23 health may also be worse or deteriorating at a faster rate. Compliance is important because it
48
49 24 represents a gap between the availability of best treatment and impact of treatment on the
50
51 25 consequences. Less compliant patients may require different behavioural or system-based
52
53 26 approaches to encourage compliance and better reporting and monitoring.
54
55
56
57
58
59
60

1
2
3 1 As expected due to the lower prevalence, the sample of haemophilia B patients in this analysis
4
5 2 is smaller than the haemophilia A cohort, and therefore differences in joint bleed prevalence
6
7 3 and HJHS between patients with haemophilia A and B should be interpreted with caution.
8
9 4 Those with haemophilia B may present with a milder bleeding phenotype than that of
10
11 5 haemophilia A regardless of severity or treatment [32, 35, 36]. In addition people with
12
13 6 haemophilia B may display less severe levels of haemarthropathy, with differences in the
14
15 7 specific pathophysiological mechanisms of joint disease underlined by different rates of joint
16
17 8 deterioration and severity [37]. Direct comparison between disease types is limited and
18
19 9 therefore further research is needed to explore whether the lower bleed rates and better joint
20
21 10 health in people with haemophilia B suggested in this study can be confirmed.

22
23
24
25 11 History of spontaneous and traumatic bleeding could not be separated, owing to data reporting
26
27 12 methods within Haemtrack. Whilst prophylaxis protects against spontaneous bleeding there is
28
29 13 still a proportion of these treatment compliant adults reporting up to four joint bleeds in the 12
30
31 14 month study period. Haemarthrosis may occur as individual joint events, but our data
32
33 15 highlights the burden on overall joint disease. A previous history of developing inhibitors and
34
35 16 a history of on-demand treatment now using secondary prophylaxis may predispose patients
36
37 17 to higher levels of joint disease and greater risk of subsequent haemarthrosis [11]. Further
38
39 18 research is required therefore to understand the bleeding profile and burden of disease in
40
41 19 adults with established joint disease and previous inhibitor status.

42
43
44 20 A further limitation is between-centre variability in HJHS assessment [38]. HJHS data from
45
46 21 different haemophilia centres may be subject to inter-centre scoring variability, although
47
48 22 workshops have been conducted in the UK to decrease inter-centre variability in HJHS
49
50 23 scoring. Furthermore, we are unable to confirm the influence of other factors such as the
51
52 24 presence of co-morbid musculoskeletal conditions on HJHS data. UKHCDO NHD data was
53
54 25 also requested from those with moderate disease but there was insufficient data to include in
55
56 26 the analysis. Future comparison by disease severity (severe and moderate) may provide
57
58 27 further insight of those most at risk of haemarthropathy.
59
60

1
2
3 1
4
5
6 2
7
8 3
9
10
11 4
12
13 5
14
15 6
16
17 7
18
19 8
20
21 9
22
23 10
24
25
26 11
27
28 12
29
30 13
31
32 14
33
34
35 15
36
37 16
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Clinical implication and conclusion:

In a UK cohort of Haemtrack compliant patients with severe haemophilia and without a current inhibitor, only 70% of children and 30% of adults remained haemarthrosis free during 2018. Haemarthrosis was most likely to be reported in the knee joint in children with haemophilia A, the ankle joint in children with haemophilia B, the elbow and ankle joint in adults with haemophilia A, and the elbow joint in adults with haemophilia B. Overall higher HJHS were reported for the ankle joint compared to the knee and elbow, suggesting that the ankle joint is the most severely compromised joint in people with haemophilia.

Investigation of impact on function and potential interventions that lessen the burden of disease are warranted. Future clinical studies would also benefit from understanding the bleeding profiles of those who do not meet compliance criteria for Haemtrack or other database-linked bleed data to obtain the true prevalence of haemarthrosis and joint disease.

1
2
3 **1 Abbreviations**
4

5 **2 ABR:** Annual bleed rate
6

7 **3 AJBR:** Annual joint bleed rate
8

9 **4 CFC:** Clotting factor concentrate
10

11 **5 EHL:** Extended half life
12

13 **6 HJHS:** Haemophilia joint health score
14

15 **7 NHD:** National Haemophilia Database
16

17 **8 SHL:** Standard half-life
18

19 **9 UKHCDO:** United Kingdom Haemophilia Doctors Organisation
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Declarations**

2 **Ethics approval and consent to participate**

3 Ethical approval was obtained to allow access the National Haemophilia Database,
4 anonymised data. This study was approved by London Queen Square Research Ethics
5 Committee (16/LO/2251) and NHS Health research Authority (IRAS ID 206141). Individual
6 participant consent was not applicable.

7 **Consent for publication**

8 Consent to publish this paper was obtained from the UKHCDO NHD.

9 **Availability of data and materials**

10 The data that support the findings of this study are available from The National Haemophilia
11 Database (NHD) but restrictions apply to the availability of these data, which were used under
12 license for the current study, and so are not publicly available. Data are however available from
13 the corresponding author upon reasonable request and with permission of the NHD.

14 **Competing interests**

15 RAW has received registration fees and support for travel from Roche.

16 DS has received research funding from Sobi, CSL and Roche; consultancy and speakers fees
17 from Sobi and Takeda

18 EH has received speaker fees from Roche, sponsorship for travel from Sobi.

19 MJS has received research funding from Bayer; consultancy and speakers fees from Sobi and
20 Roche; registration fees and support for travel from Sobi, Pfizer and CSL.

21 HJS is a HEE/NIHR Senior Clinical lecturer and has received funding from NIHR who also
22 funded this research.

23 ACR is a NIHR Senior Investigator and has received funding from NIHR who also funded this
24 research.

25 GJC, RW, HX, BP and MR report no competing interests

1 **Funding**

2 RAW is funded by a National Institute for Health Research (NIHR) Clinical Doctoral Research
3 Fellowship (ICA-CDRF-2015-01-0120); ACR is in part supported through the NIHR Leeds
4 Biomedical Research Centre, Leeds, UK. This paper presents independent research funded
5 by the National Institute for Health Research (NIHR). The views expressed are those of the
6 authors and not necessarily those of the NHS, the NIHR or the Department of Health.

7 **Author's contributions**

8 The study was conceived by RAW, AR, GC, RW and HJS. Analysis was undertaken by
9 members of staff at the NHD (HX and BP).The manuscript was written by RAW and DS.
10 Subsequent drafts were edited and approved by RAW, DS, MJS, AR, GC, MR, EH, HJS, and
11 RW.

13 **Acknowledgements**

14 The authors would like to thank the centre directors, physiotherapists and staff of all UK
15 haemophilia centres for their hard work in collecting data and responding to data queries. We
16 would also like to thank the members of the UKHCDO Data Analysis Group for advising on
17 data interpretation; Prof Charles Hay, Prof Peter Collins, Dr Elizabeth Chalmers, Dr Ryan
18 Cheal, Prof Pratima Chowdary, Simon Fletcher, Dr Georgina Hall, Dr Dan Hart, Dr Ri Liesner,
19 Andrew McNally, Ben Palmer, Paul Sartain, Dr Martin Scott, Dr Susie Shapiro, David
20 Stephensen, Dr Hua Xiang. The staff at the National Haemophilia Database are also thanked
21 for their contribution to data collection.

23 **Author's information**

24 **ORCID (those with ORCID IDs)**

25 Richard Wilkins: 0000-0003-1885-5472

26 Anthony Redmond: 0000-0002-8709-9992

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


- 1 Heidi Siddle: 0000-0002-6015-332X
- 2 Graham Chapman: 0000-0003-3983-6641
- 3 Martin Scott: 0000-0002-0854-1309
- 4 David Stephensen: 0000-0002-6175-3343
- 5 Rebecca Walwyn: 0000-0001-9120-1438

For peer review only

1 References

1. Bolton-Maggs, P. and J. Pasi, *Haemophilias a and b*. The Lancet, 2003. **361**(9371): p. 1801-1809.
2. Biggs, R. and R. Macfarlane, *Haemophilia and related conditions: a survey of 187 cases*. British journal of haematology, 1958. **4**(1): p. 1-27.
3. Gringeri, A., B. Ewenstein, and A. Reiningger, *The burden of bleeding in haemophilia: is one bleed too many?* Haemophilia, 2014. **20**(4): p. 459-463.
4. Van Vulpen, L., K. Holstein, and C. Martinoli, *Joint disease in haemophilia: Pathophysiology, pain and imaging*. Haemophilia, 2018. **24**: p. 44-49.
5. Roosendaal, G. and F. Lafeber, *Pathogenesis of haemophilic arthropathy*. Haemophilia, 2006. **12**(s3): p. 117-121.
6. Hanley, J., et al., *Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia*. Haemophilia, 2017.
7. Manco-Johnson, M.J., et al., *Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia*. New England Journal of Medicine, 2007. **357**(6): p. 535-544.
8. Oldenburg, J., *Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens*. Blood, 2015. **125**(13): p. 2038-44.
9. Gringeri, A., et al., *A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)*. Journal of Thrombosis and Haemostasis, 2011. **9**(4): p. 700-710.
10. Srivastava, A., et al., *Guidelines for the management of hemophilia*. 2013. **19**(1): p. e1-e47.
11. Collins, P., et al., *Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study*. Journal of Thrombosis and Haemostasis, 2010. **8**(1): p. 83-89.
12. Skinner, M.W., et al., *Achieving the unimaginable: Health equity in haemophilia*. Haemophilia, 2019.
13. Skinner, M.W., *WFH: closing the global gap—achieving optimal care*. Haemophilia, 2012. **18**: p. 1-12.
14. Ebbert, P.T., et al., *Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors*. Haemophilia, 2020. **26**(1): p. 41-46.
15. Chowdary, P., *Extended half-life recombinant products in haemophilia clinical practice—Expectations, opportunities and challenges*. Thrombosis Research, 2019.
16. Scott, M.J., et al., *Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study*. Haemophilia, 2019. **25**(2): p. 205-212.
17. Berntorp, E., et al., *European retrospective study of real-life haemophilia treatment*. Haemophilia, 2017. **23**(1): p. 105-114.
18. Poonnoose, P., et al., *Correlating clinical and radiological assessment of joints in haemophilia: results of a cross sectional study*. Haemophilia, 2016. **22**(6): p. 925-933.
19. Thornburg, C.D., N.A.J.P.p. Duncan, and adherence, *Treatment adherence in hemophilia*. Patient preference adherence, 2017. **11**: p. 1677.
20. Hay, C., et al., *The haemtrack home therapy reporting system: Design, implementation, strengths and weaknesses: A report from UK Haemophilia Centre Doctors Organisation*. Haemophilia, 2017. **23**(5): p. 728-735.

- 1 21. UKHCDO. *united kingdom haemophilia centre doctors organisation*. 2020
2 [cited 2020 05/04/2020]; Available from: <http://www.ukhcdo.org/nhd/>.
- 3 22. UKHCDO, *UKHCDO Annual Report 2019, including bleeding disorder*
4 *statistics 2019*.
- 5 23. Richards, M., et al., *A United Kingdom Haemophilia Centre Doctors'*
6 *Organization guideline approved by the British Committee for Standards in*
7 *Haematology: guideline on the use of prophylactic factor VIII concentrate in*
8 *children and adults with severe haemophilia A*. *British journal of haematology*,
9 2010. **149**(4): p. 498-507.
- 10 24. Boehlen, F., L. Graf, and E. Berntorp, *Outcome measures in haemophilia: a*
11 *systematic review*. *European Journal of Haematology*, 2014. **93**: p. 2-15.
- 12 25. Hilliard, P., et al., *Hemophilia joint health score reliability study*. *Haemophilia*,
13 2006. **12**(5): p. 518-525.
- 14 26. Aspdahl, M., et al., *Comparison of joint status in children with haemophilia A*
15 *using ultrasound and physical examination*. *European Journal of*
16 *Physiotherapy*, 2018. **20**(3): p. 172-177.
- 17 27. Hakobyan, N., et al., *Pathobiology of hemophilic synovitis I: overexpression of*
18 *mdm2 oncogene*. *Blood*, 2004. **104**(7): p. 2060-2064.
- 19 28. Roosendaal, G., et al., *Blood-induced joint damage: a canine in vivo study*.
20 *Rheumatism: Official Journal of the American College of Rheumatology*,
21 1999. **42**(5): p. 1033-1039.
- 22 29. Hooiveld, M., et al., *Blood-induced joint damage: longterm effects in vitro and*
23 *in vivo*. *The Journal of rheumatology*, 2003. **30**(2): p. 339-344.
- 24 30. Pasta, G., et al., *Orthopaedic management of haemophilia arthropathy of the*
25 *ankle*. *Haemophilia*, 2008. **14**(s3): p. 170-176.
- 26 31. Rodriguez-Merchan, E.C., *Management of hemophilic arthropathy of the*
27 *ankle*. *Cardiovascular and Hematological Disorders - Drug Targets*, 2017.
28 **17**(2): p. 111-118.
- 29 32. Mannucci, P. and M. Franchini, *Is haemophilia B less severe than*
30 *haemophilia A?* *Haemophilia*, 2013. **19**(4): p. 499-502.
- 31 33. Feldman, B.M., et al., *Tailored frequency-escalated primary prophylaxis for*
32 *severe haemophilia A: results of the 16-year Canadian Hemophilia*
33 *Prophylaxis Study longitudinal cohort*. *Lancet Haematol*, 2018. **5**(6): p. e252-
34 e260.
- 35 34. Kuijlaars, I.A.R., et al., *Monitoring joint health in haemophilia: Factors*
36 *associated with deterioration*. *Haemophilia*, 2017. **23**(6): p. 934-940.
- 37 35. Santagostino, E., et al., *Severe hemophilia with mild bleeding phenotype:*
38 *molecular characterization and global coagulation profile*. *Journal of*
39 *Thrombosis and Haemostasis*, 2010. **8**(4): p. 737-743.
- 40 36. Castaman, G. and D.J.h. Matino, *Hemophilia A and B: molecular and clinical*
41 *characteristics of similar, but different diseases*. *Haematologica*, 2019: p.
42 haematol. 2019.221093.
- 43 37. Melchiorre, D., et al., *Clinical, instrumental, serological and histological*
44 *findings suggest that hemophilia B may be less severe than hemophilia A*.
45 *Haematologica*, 2016. **101**(2): p. 219-225.
- 46 38. Nijdam, A., et al., *Using routine Haemophilia Joint Health Score for*
47 *international comparisons of haemophilia outcome: standardization is needed*.
48 *Haemophilia* 2016. **22**(1): p. 142-147.



er review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement

Checklist of items that should be included in reports of observational studies

Section/Topic	Item No	Recommendation	Reported on Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up and data collection	8-9
		(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	
Participants	6	<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	7-9
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
Variables	7	(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	n/a
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Data sources/measurement	8*	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7,8
		For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	8,9
Study size	10	Explain how the study size was arrived at	10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
		(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	
Statistical methods	12	<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	n/a
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	

Section/Topic	Item No	Recommendation	Reported on Page No
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	10
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	n/a
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	n/a
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	n/a
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	n/a
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11,12
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
Other Information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	21

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.